RT Journal Article
SR Electronic
T1 Lipidomics for diagnosis and prognosis of pulmonary hypertension
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.17.23289772
DO 10.1101/2023.05.17.23289772
A1 Bordag, Natalie
A1 Nagy, Bence Miklos
A1 Zügner, Elmar
A1 Ludwig, Helga
A1 Foris, Vasile
A1 Nagaraj, Chandran
A1 Biasin, Valentina
A1 Bodenhofer, Ulrich
A1 Magnes, Christoph
A1 Maron, Bradley A.
A1 Ulrich, Silvia
A1 Lange, Tobias J.
A1 Hötzenecker, Konrad
A1 Pieber, Thomas
A1 Olschewski, Horst
A1 Olschewski, Andrea
YR 2023
UL http://medrxiv.org/content/early/2023/11/29/2023.05.17.23289772.abstract
AB Background Pulmonary hypertension (PH) poses a significant health threat with high morbidity and mortality, necessitating improved diagnostic tools for enhanced management. Current biomarkers for PH lack functionality and comprehensive diagnostic and prognostic capabilities. Therefore, there is a critical need to develop biomarkers that address these gaps in PH diagnostics and prognosis.Methods To address this need, we employed a comprehensive metabolomics analysis in 233 blood based samples coupled with machine learning analysis. For functional insights, human pulmonary arteries (PA) of idiopathic pulmonary arterial hypertension (PAH) lungs were investigated and the effect of extrinsic FFAs on human PA endothelial and smooth muscle cells was tested in vitro.Results PA of idiopathic PAH lungs showed lipid accumulation and altered expression of lipid homeostasis-related genes. In PA smooth muscle cells, extrinsic FFAs caused excessive proliferation and endothelial barrier dysfunction in PA endothelial cells, both hallmarks of PAH.In the training cohort of 74 PH patients, 30 disease controls without PH, and 65 healthy controls, diagnostic and prognostic markers were identified and subsequently validated in an independent cohort. Exploratory analysis showed a highly impacted metabolome in PH patients and machine learning confirmed a high diagnostic potential. Fully explainable specific free fatty acid (FFA)/lipid-ratios were derived, providing exceptional diagnostic accuracy with an area under the curve (AUC) of 0.89 in the training and 0.90 in the validation cohort, outperforming machine learning results. These ratios were also prognostic and complemented established clinical prognostic PAH scores (FPHR4p and COMPERA2.0), significantly increasing their hazard ratios (HR) from 2.5 and 3.4 to 4.2 and 6.1, respectively.Conclusion In conclusion, our research confirms the significance of lipidomic alterations in PH, introducing innovative diagnostic and prognostic biomarkers. These findings may have the potential to reshape PH management strategies.Competing Interest StatementSeveral authors (NB, CM, AO, BMN, HO) are inventors of the patent: Biomarker for the diagnosis of pulmonary hypertension (PH) WO2017153472A1 (priority date 09.03.2016, granted in US, KR, JP, pending in CA, EP, AU) being jointly held by CBmed Gmbh, Joanneum Research Forschungsgesellschaft mbH, Medical University Graz and Ludwig Boltzmann Gesellschaft GmbH. The authors received no personal financial gain from the patent. During work on this publication NB was partially employed at CBmed GmbH. TP is chief scientific officer (CSO) of CBmed GmbH. EZ and CM were employed at Joanneum Research Forschungsgesellschaft mbH. The employing companies provided support in the form of salaries, materials and reagents but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. VF received honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Janssen, Chiesi, BMS, and Boehringer Ingelheim and support for attending meetings, and/or travel from Janssen, MSD, and Boehringer Ingelheim outside the submitted work. CN received support for attending meetings, and/or travel from Boehringer Ingelheim and Inventiva pharma outside the submitted work. BAM reports personal fees from Actelion Pharmaceuticals, Tenax and Regeneron, grants from Deerfield Company, NIH (5R01HL139613-03, R01HL163960, R01HL153502, R01HL155096-01), Boston Biomedical Innovation Ceter (BBIC), Brigham IGNITE award, Cardiovascular Medical research Education Foundation outside the submitted work. BAM reports patent PCT/US2019/059890 (pending), PCT/US2020/066886 (pending) and 9,605,047 (granted) not licensed and outside the submitted work. SU received grants from the Swiss National Science Foundation, Zurich and Swiss Lung League, EMDO-Foundation, Orpha-Swiss, Janssen and MSD all unrelated to the present work. SU received consultancy fees and travel support from Orpha-Swiss, Janssen, MSD and Novartis unrelated to the present work. TJL reports grants for his institution from Acceleron Pharma, Gossamer Bio, Janssen-Cilag, and United Therapeutics; personal fees and non-financial support from Acceleron Pharma, AstraZeneca, Boehringer Ingelheim, Gossamer Bio, Ferrer, Janssen-Cilag, MSD, Orphacare, and Pfizer outside the submitted work. KH is a consultant at Medtronic Oesterreich GmbH outside the submitted work. TP reports grants from AstraZeneca, Novo Nordisk, Sanofi paid to the Medical University of Graz outside the submitted work. TP reports personal fees and nonfinancial support from Novo Nordisk and Roche Diagnostics outside the submitted work. HO reports grants from Bayer, Unither, Actelion, Roche, Boehringer Ingelheim, and Pfizer. HO reports personal fees and nonfinancial support from Medupdate and Mondial, AOP, Bayer, Actelion, Pfizer, Ferrer, Novartis, Astra Zeneca, Boehringer Ingelheim, Chiesi, Menarini, MSD, and GSK outside the submitted work. AO received honoraria for presentations and support for attending meetings, and/or travel from MSD outside the submitted work. No conflict of interest, financial or otherwise, are declared by the authors HL and UB.Funding StatementNB, TP disclose that part of this work has been carried out with the K1 COMET Competence Center CBmed, which is funded by the Federal Ministry of Transport, Innovation and Technology; the Federal Ministry of Science, Research and Economy; Land Steiermark (Department 12, Business and Innovation); the Styrian Business Promotion Agency; and the Vienna Business Agency. The COMET program is executed by the Oesterreichische Forschungsfoerderungs GmbH FFG. VB is supported by the Austrian Science Foundation (FWF, T1032-B34).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of the Medical University of Graz, Austria gave ethical approval for this work for the cohort GRAPH (Graz Pulmonary Hypertension Registry, identifier: 23-408ex10/11, registered at ClinicalTrials.gov (NCT01607502). The Ethics Committee of the Medical University of Graz, Austria gave ethical approval for this work for the cohort BioPersMed (Biomarkers of Personalised Medicine, identifier: 23-408ex10/11, renewed every year 24-224 ex 11/12). The Ethics Committee of the Regensburg University, Germany gave ethical approval for this work for the validation cohort (identifier 08/090). The cantonal ethical review board Zurich, Switzerland gave ethical approval for this work for the validation cohort (identifier KEK 2010-0129; 2014-0214; 2017-0476).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe author declare that all data supporting the findings in this study are available in the online Supplementary Sata 1 and online repositories. Mass spectrometric data have been deposited in https://zenodo.org under doi: 10.5281/zenodo.7857706. Data is provided de-identified and is available immediately for any purpose. The provided Sample_Name in the online Supplementary Data 1 links to the file names in the online repository and are unsuitable to identify single patients. The primary key is only known to part of the study team. Machine learning code is available immediately for any purpose on Github: https://github.com/HelgaLudwig/PHMetab. https://zenodo.org/records/7857706 https://github.com/HelgaLudwig/PHMetab 6MWDsix minute walking distanceAChacetylcholineADMAasymmetric dimethylarginineAUCarea under the curveBHBenjamini–HochbergBMIbody mass indexBNP or NT-proBNPnatriuretic peptide levelsCOcardiac outputCOPDchronic obstructive pulmonary diseaseCIcardiac indexCTEPHchronic thromboembolic pulmonary hypertensionDCdiseased control (non-PH)DLCOcVAdiffusing capacity for carbon monoxide per alveolar volume, hemoglobin correctedECARextracellular acidification rateECISelectrical cell-substrate impedance sensorEDTAethylenediaminetetraacetic acidFEV1forced expiratory volume/ 1 sFVCforced vital capacityFFAfree fatty acidsH&Ehematoxylin-eosinHChealthy controlHILIChydrophilic interaction liquid chromatographyhPAEChuman pulmonary artery endothelial cellshPASMChuman pulmonary artery smooth muscle cellsHRhazard ratioHRMShigh resolution mass spectrometryILDinterstitial lung diseaseIPAHidiopathic pulmonary arterial hypertensioniPCAindependent principal component analysisIVDin vitro diagnosticsLPClysophosphatidylcholineLPElysophosphatidylethanolamineLVleft ventricleMADmedian absolute deviationmPAPmean pulmonary arterial pressureMSmass spectrometryOCRoxygen consumption rateOPLS-DAorthogonal projections to latent structures discriminant analysisPApulmonary arteriesPAHpulmonary arterial hypertensionPAPpulmonary arterial pressurePAWPpulmonary arterial wedge pressurePBSphosphate-buffered salinePCphosphatidylcholinePDGFplatelet-derived growth factorPHpulmonary hypertensionPPPpentose phosphate pathwayPVRpulmonary vascular resistanceQCpooled from samples for quality controlRAPright atrial pressureRDWred cell distribution widthRFrandom forestRHCright heart catheterizationROCreceiver operator curveRTroom temperature (20 – 25 °C)SEMstandard error of meanSMsphingomyelinSMAsmooth muscle actinSvO2mixed venous oxygen saturationTAGtriacylglycerideTEERtransendothelial electrical resistanceTLCtotal lung capacityVWFvon-Willebrand FactorWHO FCWorld Health Organization functional classWUWood unitXGBoosteXtreme Gradient Boosting